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Abstract Interleukin-10 (IL-10) has been used in the treatment
of viral hepatitis in interferon-K (IFN-K) non-responders while
patients who have high levels of IL-10 are poorly responsive to
IFN-K. The mechanism underlying such controversial functions
of IL-10 remains unknown. Here we demonstrated that injection
of IL-10 into mice attenuated IFN-K-induced signal transducer
and activator transcription factor (STAT)1 tyrosine phosphor-
ylation in the liver. Reverse transcriptase-polymerase chain
reaction assay demonstrated that mouse liver expressed high
levels of IL-10 receptor 2 (IL-10R2) but low levels of IL-10R1.
Injection of IL-10 into mice activated STAT3 but not STAT1
tyrosine phosphorylation and induced suppressor of cytokine
signal 2 (SOCS2), SOCS3, and cytokine-inducible SH2 protein
(CIS) mRNA expression in the liver. Furthermore, overexpres-
sion of SOCS2 or SOCS3 inhibited IFN-K-induced reporter
activity in hepatic cells. These findings suggest that IL-10
inhibits IFN-K-activated STAT1 in the liver, at least in part, by
inducing SOCS2, SOCS3, and CIS expression, which may be
responsible for the resistance of IFN-K therapy in patients who
have high levels of IL-10 and recommends that IL-10 treatment
for viral hepatitis should be cautious. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Interleukin 10 (IL-10) is a pleiotropic cytokine produced by
many cell types including Th0, Th2 CD4 T cells, CD5 B
cells, thymocytes, keratinocytes, and macrophages. IL-10 ex-
erts the anti-in£ammatory e¡ect by suppressing expression of
macrophage in£ammatory proteins (reviewed in [1^3]). The
anti-in£ammatory and immunosuppressive activities of IL-10
in vivo are clearly demonstrated in IL-10-de¢cient [4] and IL-
10 receptor 2 (IL-10R2)-de¢cient (CRFB43/3) [5] mice. In
both mice, chronic colitis and splenomegaly reminiscent
were developed. IL-10 treatment has been shown to decrease
the severity of in£ammatory processes in a variety of exper-
imental models and clinical patients [6^11]. It is believed that
IL-10 exerts its function by acting on IL-10 receptors, which
consist of an K chain (IL-10RK or IL-10R1) and a L chain
(IL-10RL or IL-10R2). Upon IL-10 binding, IL-10R-associ-
ated tyrosine kinases (JAK1 and Tyk2) are activated and fol-
lowed by phosphorylating Y446 and Y496 of IL10R1, which
in turn phosphorylate signal transducer and activator tran-
scription factor (STAT)1 and STAT3. Phosphorylated
STAT1 and STAT3 form a heterodimer or homodimer, which
then translocates to the nucleus to activate the transcription
of many target genes, including suppressor of cytokine signal
3 (SOCS-3) (reviewed in [1^3]).
Recently, it has been shown that IL-10 has anti¢brogenic
and anti-in£ammatory e¡ects in the liver [12^14]. IL-10-de¢-
cient mice are more susceptible to severe CCl4-induced liver
¢brosis [13,14]. The people with possession of the A allele at
position 3627 in the IL-10 promoter region are more suscep-
tible to alcoholic liver disease [15]. IL-10 treatment has a
protective role for liver transplantation, hepatic ischemia/re-
perfusion injury, and toxic liver injury [16,17]. The molecular
mechanism underlying the protective e¡ects of IL-10 in the
liver is poorly understood. It is believed that IL-10 protects
against hepatic liver injury by suppressing NFkB activation
and subsequent expression of proin£ammatory mediators (re-
viewed in [1^3]). In addition to T cells, B cells, and macro-
phages, many cell types within the liver can synthesize IL-10.
These include Kup¡er cells [18], hepatocytes [19], and stellate
cells [20]. IL-10 expression in the liver or the levels of IL-10 in
the plasma are signi¢cantly elevated in many chronic liver
diseases including viral hepatitis [21]. High expression of
IL-10 has also been associated with the IL-10 polymorphisms
3627*C allele [22] and GCC haplotype [23,24]. Although IL-
10 has been shown to play an important role in anti-in£am-
matory and anti-¢brosis in the liver [12^14], patients who are
genetically predisposed to high IL-10 production have a poor
response to IFN-K [24]. In attempting to de¢ne the mecha-
nism by which IL-10 may antagonize IFN-K-action, we also
reviewed the IFN-K signaling pathway. The binding of IFN-K
to its receptor activates the receptor-associated JAK tyrosine
kinases. This receptor^kinase complex interacts with and ac-
tivates the SH2-containing cytoplasmic STAT transcription
factors (such as STAT1, 2, or 3). Activated STAT proteins
then form homo- or hetero-complexes that translocate to the
nucleus to activate the transcription of many target genes,
including antiviral proteins Mx, PKR, and 5-3 OAS (reviewed
in [25^27]). The essential role of IFN-activated STAT1 in
antiviral and anti-tumor activities is clearly demonstrated in
STAT1 knockout mice [28,29]. In these mice, IFN signaling is
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defective and the innate response to viral or bacterial infection
is absent.
In this study, we demonstrated that injection of IL-10 atte-
nuated IFN-K-induced STAT1 tyrosine phosphorylation in
the liver, and induction of suppressor of cytokine signal 2
(SOCS2) and SOCS3 was, at least in part, responsible for
such inhibition. This may explain a poor response to IFN-K
in patients with high levels of IL-10 in the serum [24].
2. Materials and methods
2.1. Materials
Female ICR mice (15^20 g) were purchased from Harlan Sprague-
Dawley, Inc. (Indianapolis, IN, USA). STAT1 and STAT3 antibodies
were purchased from Upstate Biotechnology (Lake Placid, NY,
USA). Anti-phosphotyrosine-STAT1 (Tyr701) and anti-phosphotyro-
sine-STAT3 (Tyr703) antibodies were obtained from Bio-lab (Beverly,
MA, USA). IL-10 and IFN-K were purchased from Bioscience Inter-
national (Camarillo, CA, USA). The SOSC2 and SOCS3 expression
vectors were kindly provided by Dr. Douglas Hilton (The Walter and
Eliza Hall Institute of Medical Research, Vic., Australia). The IFN-
responsive reporter gene (pISG54-LUC), which was constructed by
incorporating a fragment of the hamster ISG54 promoter from
3429 to +31 [30] fused to the luciferase gene, was kindly provided
by Dr. Levy (New York University School of Medicine, New York,
USA).
2.2. Western blot analysis
Tissues were homogenized in lysis bu¡er (30 mM Tris, pH 7.5,
150 mM NaCl, 1 mM phenylmethylsulfonyl £uoride, 1 mM Na3VO4,
1% Nonidet P-40, 10% glycerol) and then centrifuged for 10 min at
4‡C. The protein concentration of the supernatant (protein fraction)
was calculated using the Bio-Rad protein assay. An aliquot of 40 Wg
of protein was mixed with an equivalent volume of 2Uprotein loading
bu¡er containing L-mercaptoethanol and boiled for 5 min before
loading onto an SDS/8%polyacrylamide gel. After electrophoresis,
proteins were transferred onto nitrocellulose membranes and blotted
against primary antibodies. Membranes were washed with TPBS
(0.05%, vol./vol.) Tween 20 in phosphate-bu¡ered saline (pH 7.4)
and incubated with a 1:4000 dilution of horseradish peroxidase-con-
jugated secondary antibodies for 45 min. Protein bands were visual-
ized by an enhanced chemiluminescence reaction (Amersham Pharma-
cia Biotech, Piscataway, NJ, USA).
2.3. Transient transfection and luciferase assay
Transient transfections were performed by using the lipofectin re-
agent (Gibco BRL) as recommended by the manufacturer. Brie£y, the
cells were washed twice with Opti-MEN I reduced-serum medium
(Gibco BRL). For luciferase assays, 2 Wg of plasmid DNA per
35 mm plate was cotransfected with 1 Wg of a L-galactosidase vector
(Promega, Madison, WI, USA) to allow for adjustments of transfec-
tion e⁄ciency. After transfection, the cells were continuously incu-
bated in reduced-serum medium for 8 h, then changed to normal
growth medium for 16 h. Cells were stimulated with IFN-K and har-
vested after an additional 8 h period, lysed by freeze-thawing, and
assayed for L-galactosidase and luciferase activities. L-Galactosidase
activity was assayed as described by Sambrook et al. (1989) [31] and
was expressed as A420UWg protein31Uh31U100. Protein concentra-
tions were determined using the Bio-Rad protein assay solution as
described by the manufacturer, and bovine serum albumin as stan-
dard. Luciferase activity was assayed using the luciferase enzyme as-
say system (Promega) on a luminometer (Bio-Rad). All values of lu-
ciferase in cell extracts were normalized to the L-galactosidase activity
in the same extracts. All transfections were replicated at least three
times with similar results.
2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
The RT-PCR was carried out as described previously [32]. The
following mouse primer pairs were used: IL-10R1 (508 bp): forward
(5P AGG CAG AGG CAG CAG GCC CAG CAG AA 3P) and
reverse (5P TGG AGC CTG GCT AGC TGG TCA CAG 3P) ; IL-
10R2 (400 bp): forward (5P GCC AGC TCT AGG AAT GAT TC 3P)
and reverse (5P AAT GTT CTT CAA GGT CCA C 3P) ; SOCS1 (350
bp): forward (5P CAC GCC GAT TAC CGG CGC ATC 3P) and
reverse (5P GCT CCT GCA GCG GCC GCA CG 3P) ; SOCS2 (300
bp): forward (5P AAG ACA TCA GCC GGG CCG ACT A 3P) and
reverse (5P GTC TTG TTG GTA AAG GTA GTC 3P) ; SOCS3 (450
bp): forward (5P GGA CCA GCG CCA CTT CTT CAC 3P) and
reverse (5P TAC TGG TCC AGG AAC TCC CGA 3P) ; cytokine-
inducible SH2 protein (CIS) (213 bp): forward (5P TAG TGA CTC
GGT GCT GCC TAT C 3P) and reverse (5P GTG CCT GGC TCA
GTC AGA GTT G 3P).
3. Results
3.1. IL-10 attenuates IFN-K-induced STAT1 tyrosine
phosphorylation without a¡ecting the levels of STAT1
protein expression in the liver
To test whether IL-10 regulates IFN-K signaling pathway in
the liver, ICR mice were intravenously injected with IL-10 for
various time periods and followed by administration of IFN-K
for 30 min. Liver extracts were prepared and IFN-K-activated
STAT1 was analyzed. As phosphorylation of STAT1 at
Tyr701 is essential for dimerization and DNA binding of
STAT induced by IFN-K, phosphorylation at this site is an
excellent marker of the IFN-K signaling pathway [25^27]. As
shown in Fig. 1, injection of IL-10 for 2 h markedly attenu-
ated IFN-K-induced STAT1 tyrosine phosphorylation in the
liver. Injection of IL-10 for 4 or 8 h almost completely abol-
ished IFN-K-induced STAT1 tyrosine phosphorylation. The
same density of unphosphorylated STAT1 in the bottom pan-
el indicated that IL-10 and/or IFN-K treatment did not a¡ect
the levels of STAT1 protein expression in the liver. These
¢ndings indicate that IL-10 is able to suppress the IFN-K
signaling pathway in the liver in vivo.
3.2. Mouse liver expresses high levels of IL-10R2 but low levels
of IL-10R1
The above data suggested that IL-10 might directly target
the liver. To further con¢rm this notion, we examined whether
mouse liver expresses IL-10R. As shown in Fig. 2, mouse
spleen and thymus expressed high levels of both IL-10R1
and IL-10R2, while the liver expressed high levels of
IL-10R2 but low levels of IL-10R1. These ¢ndings suggest
that mouse liver expresses both IL-10R1 and IL-10R2.
3.3. IL-10 activates STAT3 but not STAT1 tyrosine
phosphorylation in the liver and spleen
It has been shown that IL-10 activated STAT1 and STAT3
Fig. 1. IL-10 attenuates IFN-K-induced STAT1 tyrosine phosphory-
lation in the liver in vivo. Mice were injected intravenously with IL-
10 (40 Wg/kg body weight (bwt)) for various time periods as indi-
cated and followed by injection of IFN-K (40 Wg/kg bwt) for 30
min. Liver extracts were prepared and then subjected to Western
blot analysis by using anti-phospho-STAT1 (Tyr701) or anti-STAT1
antibodies. Blots shown are representative of three independent ex-
periments.
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in a variety of cells [1^3], but the IL-10 signaling pathway in
the liver remains unknown. To determine IL-10 signal trans-
duction in the liver, mice were intravenously injected with
IL-10 and phosphorylation of STATs was detected. As shown
in Fig. 3, injection of IL-10 markedly induced STAT3 but not
STAT1 tyrosine phosphorylation in the liver and spleen, while
the positive control IFN-K markedly activated STAT1 in both
the liver and spleen. Interestingly, IFN-K activated STAT3 in
the spleen but not in the liver. The unchanged levels of
STAT1 and STAT3 proteins in the liver and spleen indicated
that IL-10 treatment did not a¡ect the levels of STAT1 and
STAT3 protein expression. These ¢ndings demonstrate that
IL-10 is able to activate STAT3 tyrosine phosphorylation in
the liver and spleen.
3.4. IL-10 induces SOCS2, SOCS3, and CIS mRNA
expression in the liver
It has been shown that IL-10 was able to induce SOCS
mRNA expression in a variety of cells [33,34], we asked
whether IL-10 could also induce SOCS mRNA expression
in the liver. As shown in Fig. 4, injection of IL-10 markedly
induced SOCS2, SOCS3, and CIS mRNA expression in the
liver, whereas the SOCS1 mRNA was not induced. The peak
of induction of SOCS2 and SOCS3 mRNA expression oc-
curred after 8 h stimulation while the peak for CIS mRNA
induction was between 2 and 8 h stimulation. After 24 h
stimulation, the levels of SOCS2, SOCS3, and CIS mRNA
returned to the control levels. The unchanged intensity of
the L-actin in each lane indicated that the observed increase
in SOCS2, SOCS3, and CIS mRNA was real and not the
result of uneven loading. These ¢ndings indicate that IL-10
was able to induce expression of SOCS2, SOCS3, and CIS
mRNAs in the liver in vivo.
3.5. Overexpression of SOCS2 or SOCS3 attenuates
IFN-K-activated reporter activity
Induction of SOCS3 has been implicated in IL-10 suppres-
sion of IFN-K signaling pathway [33,34]. Here we examined
Fig. 2. Mouse liver expresses high levels of IL-10R2 but low levels
of IL-10R1. Total RNA was isolated from mouse liver, spleen, or
thymus, and then subjected to RT-PCR by using mouse IL-10R1 or
IL-10R2 primers, as described in Section 2. The PCR products were
run on a 1.5% agarose gel and visualized by staining with ethidium
bromide.
Fig. 3. IL-10 activates STAT3 but not STAT1 tyrosine phosphoryla-
tion in the liver and spleen in vivo. Mice were injected intravenously
with IL-10 (40 Wg/kg bwt) for various time periods as indicated, or
injected with IFN-K (40 Wg/kg bwt) for 30 min. Liver or spleen ex-
tracts were prepared and then subjected to Western blot analysis by
using anti-phospho-STAT1 (Tyr701), anti-phospho-STAT3 (Tyr727),
anti-STAT1 or anti-STAT3 antibodies. Blots shown are representa-
tive of three independent experiments.
Fig. 4. IL-10 induces expression of SOCS2, SOCS3, and CIS
mRNAs in the liver in vivo. Mice were injected intravenously with
IL-10 (40 Wg/kg, bwt) for various time periods as indicated. Total
RNA was prepared from the liver and subjected to RT-PCR analy-
sis by using various primer pairs as described in Section 2. The pho-
tograph shown is representative of two independent experiments.
Fig. 5. Overexpression of SOCS2 or SOCS3 attenuates IFN-K-acti-
vated reporter activity in HepG2 cells. HepG2 cells were transfected
with pISG54-Luc alone, or cotransfected with SOCS2 or SOCS3
expression vectors. After transfection for 16 h, cells were treated
with IFN-K (250 units/ml) for 8 h. Cell extracts were then harvested
and assayed for luciferase activity. C (control) represents transfec-
tion with pISG54-Luc alone without IFN-K stimulation. Values
shown are means þ S.E.M. from three independent experiments, ex-
pressed as fold changes over controls. Signi¢cant di¡erences from
the IFN-K stimulation group are indicated by asterisks; i.e., * de-
notes P6 0.01.
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whether overexpression of SOCS2 or SOCS3 also attenuated
IFN-K-activated reporter activity in HepG2 cells. As shown in
Fig. 5, IFN-K treatment markedly induced ISG54-luciferase
activity (about 7 fold control). Cotransfection of SOCS2 or
SOCS3 signi¢cantly inhibited IFN-K-induced ISG54-luciferase
activity. These ¢ndings suggest that induction of SOCS2 or
SOCS3 in the liver by IL-10 may be, at least in part, respon-
sible for IL-10 suppression of IFN-K-activated STAT1.
4. Discussion
Although it has been shown that IL-10 has anti-¢brogenic
and anti-in£ammatory e¡ects in the liver, IL-10 signaling
pathway in the liver has not been explored. Here we demon-
strate that mouse liver expresses both IL-10R1 and IL-10R2,
and injection of IL-10 markedly activated STAT3 but not
STAT1 tyrosine phosphorylation in the liver. These ¢ndings
suggest that IL-10 can directly target the liver. Since the
STAT3 activation was measured in the whole liver extracts,
it remains to be determined whether IL-10 activated STAT3
in hepatocytes or other hepatic cells. However, the whole liver
extracts are largely representative of hepatocytes, it is very
likely that IL-10 can activate STAT3 in hepatocytes in vivo.
Further studies will be required to con¢rm this notion.
STAT3 activation by IL-6 has been shown to initiate liver
regeneration and protect liver injury [35,36]. Therefore, in
addition to its anti-in£ammatory e¡ect, IL-10 activation of
STAT3 in the liver may also be involved in the protective
role of IL-10 in liver transplantation, hepatic ischemia/reper-
fusion injury, and toxic liver injury [16,17].
The molecular mechanism by which IL-10 attenuates IFN-
K signaling in the liver in vivo was also explored in this paper.
Several mechanisms responsible for inhibition of the JAK-
STAT signaling pathway have been proposed. For example,
activated JAK-STAT can be attenuated by (1) dephosphory-
lation [37^39], (2) proteolytic degradation [40,41], (3) inhibi-
tory molecules such as SOCS/JAB/SSI/CIS [42^44], which are
relatively small proteins that contain a central SH2 domain
and a conserved C-terminal SOCS-box. It is believed that
SOCS and CIS attenuated the JAK-STAT signaling pathway
by binding to the phosphorylated tyrosine residues on JAK
proteins [42^44]. Induction of inhibitory protein SOCS3 has
been implicated in IL-10 suppression of IFN-K-activated
STAT1 in human monocytes [33] and neutrophils [34] in vitro.
Two lines of evidence from this report suggest that SOCS2
and SOCS3 may also be involved in IL-10 suppression of
IFN-K-activated STAT1 in the liver in vivo. First, injection
of IL-10 induced expression of SOCS2, SOCS3, and CIS
mRNAs. Second, overexpression of SOCS2 or SOCS3 attenu-
ated IFN-K-activated reporter activity in hepatic cells. How-
ever, how IL-10 induces SOCS2, SOCS3, and CIS mRNAs in
the liver in vivo remains unknown. It has been shown that IL-
10 only selectively induces SOCS3 in human monocytes [33]
and neutrophils [34] in vitro, and this induction is rapid and
independent of STAT1/STAT3 phosphorylation. Here we
have shown that IL-10 was able to induce not only SOCS3
but also SOCS2 and CIS in the liver in vivo, the peak of
induction observed at 8 h after injection. This suggests that
IL-10 induction of SOCS in the liver in vivo may be indirect.
Further studies will be required to clarify this mechanism.
In summary, in the present paper, we demonstrated for the
¢rst time that IL-10 inhibits IFN-K-activated STAT1 in the
liver in vivo. These ¢ndings may have two clinical implica-
tions. First, IL-10 inhibition of IFN-K signaling pathway in
the liver may explain why patients who are genetically predis-
posed to high IL-10 production have a poor response to IFN-
K [24]. Second, current forms of IL-10 treatment for viral
hepatitis [45,46] must be carefully designed. A combination
of IL-10 and IFN-K treatment for viral hepatitis should be
avoided. It has been reported that IL-10 also attenuated IFN-
K-activated STAT1 in human monocytes [33] and neutrophils
[34], which may further decrease the antiviral activity of IFN-
K in vivo.
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